(Q44578051)

4 December 2017

HER2 in resected gastric cancer: Is there prognostic value? (English)

1 reference

4 December 2017

10

1 reference

4 December 2017

Sarah B Fisher

1

0 references

author name string

Kevin E Fisher

2

1 reference

4 December 2017

Malcolm H Squires

3

1 reference

4 December 2017

Sameer H Patel

4

1 reference

4 December 2017

David A Kooby

5

1 reference

4 December 2017

Bassel F El-Rayes

6

1 reference

4 December 2017

Kenneth Cardona

7

1 reference

4 December 2017

Maria C Russell

8

1 reference

4 December 2017

Charles A Staley

9

1 reference

4 December 2017

Shishir K Maithel

11

1 reference

4 December 2017

10 October 2013

1 reference

Journal of Surgical Oncology

4 December 2017

1 reference

4 December 2017

109

1 reference

4 December 2017

2

1 reference

4 December 2017

61-66

1 reference

4 December 2017

Global cancer statistics

1 reference

21 January 2018

Cancer statistics, 2012

1 reference

Preoperative and postoperative chemotherapy for gastric cancer

21 January 2018

1 reference

Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients

21 January 2018

1 reference

Gastric adenocarcinoma surgery and adjuvant therapy

21 January 2018

1 reference

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

21 January 2018

1 reference

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial

21 January 2018

1 reference

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection

21 January 2018

1 reference

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial

21 January 2018

1 reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

Current approaches and future directions in the treatment of HER2-positive breast cancer

21 January 2018

1 reference

Trastuzumab in gastric cancer

21 January 2018

1 reference

Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer

21 January 2018

1 reference

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

21 January 2018

1 reference

A study of HER2 gene amplification and protein expression in gastric cancer

21 January 2018

1 reference

Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens.

21 January 2018

1 reference

Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer

21 January 2018

1 reference

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial

21 January 2018

1 reference

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction

21 January 2018

1 reference

HER2 testing in gastric cancer

21 January 2018

1 reference

Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial

21 January 2018

1 reference

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors

21 January 2018

1 reference

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 January 2018

1 reference

Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.23456

1 reference

4 December 2017

1 reference